UAMOCS 1–2 populations could benefit from BCL‐2 inhibitors (Venetoclax) combining with demethylating agents (AZA) (Fig. 5F), except monocyte‐type AML (M4/M5). Here, BCL2 is linked to acute myeloid leukemia.